การใช้ยาต้านเกร็ดเลือดในโรคสมองขาดเลือด (Antiplatelet Drugs in Ischemic Stroke)
Article Sidebar
Main Article Content
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
The International Stroke Trial (IST): andomized trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-81.
CAST: randomised placebo-controlled trial of earl aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997; 349: 1641-9.
Diener HC. Stroke prevention: antiplatelet and antithrombolytic therapy. In: Morgenstern LB, editor. Philadelphia: WB Saunder company; 2000. p. 475-94.
Peto R, Grey R, Collins R. Randomized trial of prophylactic daily aspirin in British male doctors. Med 1988; 296: 313-16.
Steering Committee of the Physicians' Health Study. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321: 129-35.
Antiplatelet trialist collaborative group. Collative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med 19888; 294: 320-31.
United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: Final results. UK-TIA Study Group. J Neurol Neurosurg Psychiatr 1991; 54: 1044-54.
Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol 1988; 12(6 Suppl A): 3A-13A.
Algra J, Gijn V. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia. J Neurol Neurosurg Psychiatry1996; 60: 197-9.
Algra J, Gijn V. Cumulative meta-analysis of aspirin efficacy after cerebral ischemia of arterial origin. J Neurol Neurosurg. Psychiatry 1999; 66: 255.
Gent M, Blakely JA, Easton JD, Ellis OJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-20.
Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501-7.
นิพนธ์ พวงวรินทร์, อดุลย์ วิริยเวชกุล. Acute stroke maกagement ในนิพนธ์ พวงวรินทร์ บรรณาธิการ. โรคหลอด เลือดสมอง. พิมพ์ครั้งที่ 2. กรุงเทพมหานคร: เรือนแก้วการพิมพ์; 2544. หน้า 467-94.
A randomised blinded trial of Clopidogrel versus Aspin in Patients at Risk of Ischaemic Events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high - risk patients (MATCH): randomised double-blind placebo-controlled trial. Lancet 2004; 364: 331-7.
The European Stroke Prevention Study (ESPS): Principle end-points. Lancet 1987; 2: 1351-4.
Sivenius J, Cunha L, Diener HC, Forbes C, Laakso M, Lowenthal A, et al. Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group. Acta Neurol Scand 1999; 99: 54-60.
Gotoh F, Tohgi H, Hirai S. Cilostazole Stroke Prevention study: a placebo-controlled double blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-57.